Progression of respiratory syncytial virus infection monitored by fluorescent quantum dot probes

Nano Letters

Volumn 5, Issue 4, 2005, Pages 591-595

  Bentzen, Elizabeth L ^a   House, Frances ^b   Utley, Thomas J ^b   Crowe Jr , James E ^b   Wright, David W ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL TRAFFICKING; CONFOCAL MICROSCOPY; FLUORESCENT QUANTUM DOT PROBES; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

CELLS; EMISSION SPECTROSCOPY; FLUORESCENCE; GENES; PROTEINS; SEMICONDUCTOR QUANTUM DOTS; VACCINES; VIRUSES;

PULMONARY DISEASES;

ATTACHMENT PROTEIN G; FLUORESCENT DYE; QUANTUM DOT; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ARTICLE; CELL LINE; CHEMISTRY; HUMAN; PHYSIOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS REPLICATION;

CELL LINE; FLUORESCENT DYES; HUMANS; QUANTUM DOTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 18144401308     PISSN: 15306984     EISSN: None     Source Type: Journal    
DOI: 10.1021/nl048073u     Document Type: Article

References (24)

1. Wu, X.; Liu, H.; Liu, J.; Haley, K. N.; Treadway, J. A.; Larson, J. P.; Ge, N.; Peale, F.; Bruchez, M. P. Nat. Biotech. 2002, 21, 41-46.
2. Goldman, E. R.; Balighian, E. D.; Mattoussi, H.; Kuno, M. K.; Mauro, J. M.; Tran, P. T.; Anderson, G. P. J. Am. Chem. Soc. 2002, 124, 41-46.
3. Parak, W. J.; Boudreau R.; Le Gros, M.; Gerion, D.; Zanchet, D.; Micheel, C. M.; Williams, S. C.; Alivisatos, A. P.; Larabell, C. Adv. Mater. 2002, 14, 41-46.
4. Kim, S.; Lim, Y. T.; Soltesz, E. G.; De Grand, A. M.; Lee, J.; Nakayama, A.; Parker, J. A.; Michaljevic, T.; Laurence, R. G.; Dor, D. M.; Cohn, L. H.; Bawendi, M. G.; Frangioni, J. V. Nat. Biotech. 2002, 74, 41-46.
5. Davidson, T. Respiratory Syncytial Virus. In Gale Encyclopedia of Medicine, Olendorf, D., Jeryan, C., Boydon, K., Fyke, M. K., Eds.; Gale Group: Detroit, MI, 1999; Vol. 4, pp 2478-2480.
6. Falsey, A. R.; Walsh, E. E. Clin. Microbiol. Rev. 2000, 13, 371-384.
7. Hruska, J. F.; Bernstein, J. M.; Douglas, R. G., Jr.; Hall, C. B. Antimicrob. Agents Chemother. 1980, 17, 770-775.
8. Durbin, A. P.; Karron, R. A. Vaccines 2003, 37, 1668-1677.
9. th Ed.; Fields, B. N., Knipe, D. M., Howley, P. M., Griffin, D. E., Eds.; Lippincott Williams & Wilkins; Philadelphia, 2001; Vol.2, pp 1443-1485.
10. Hull, J.; Hacking, D. J. Infec. 2002, 45, 18-24.
11. 4 primary, 1:1000 secondary antibodies using the 10 nM allowed for more options in the expansion of future labeling experiments.
12. Beeler, J. A.; van Wyke Coelingh, K. J. Virol. 1989, 63, 2941-2950.
13. The primary antibody for the G protein is commercially available and supplied as a purified antibody specific for the G protein of RSV A2.
14. HEp-2 cells that had been infected for four days were fixed on glass coverslips using 0.1% formaldehyde for 15 min were incubated with Fmix and G antibodies for 1 h. Cells were then washed and incubated with 605 nm QDs conjugated to goat anti-mouse antibodies and 525 nm QDs conjugated to goat anti-rabbit antibodies for 1 h. After this final incubation, cells were washed and mounted to glass slides using aqu Poly/Mount (Polysciences Inc.).
15. Bächi, T. J. Cell Biol. 1988, 107, 1689-1695.
16. Zheng, L.; Peeples, M. E.; Boucher, R. C.; Collins, P. L.; Pickles, R. J. J. Virol. 2002, 76, 5654-5666.
17. Roberts, S. R.; Campans, R. W.; Wertz, G. W. J. Virol. 1995, 69, 2667-2673.
18. HEp-2 cell monolayer cultures at 90% confluence were inoculated with RSV strain A2 at an moi of 0.0032, proportionate to that of 50 pfu in a 96-well plate. At the time indicated, cells were washed twice with PBS followed by collection by scraping the dish in PBS. The samples were centrifuged at 1500× g for 5 min; the cell pellet was lysed with 50 mM Tris HCl, 150 mM NaCl, and 1% Triton X-100 at pH8.0 with Sigma protease cocktail for 10 min on ice. The nuclei were removed by centrifugation at 13 000 rpm (Sorvall Biofuge Pico) for 5 min at 4°C. Samples were stored at -80°C until all time points were collected. Bio-Rad protein assay was performed to ensure equal loading onto a NuPAGE 4-12% nonreducing bis-tris gel, then transferred to a PVDF membrane. Membrane was probed with either MAb19 (α-RSV F), C797 (α-RSV N), or Sigma anti-actin (A5060), followed by a secondary conjugation to HRP. The Western blot was developed using SuperSignal West pico chemiluminescent substrate (Pierce). Stripping was achieved with 0.1 M glycine HCl pH 2.7 for 30 min then washing with PBS. Indicated above is the time point in hours or (-) in which no RSV was present.
19. T, for both RSV F and RSV N at each time point. Kallewaard, N. L. et al. Virology 2005, 331, 73-81.
20. Gueudin, M.; Vabret, A.; Petitjean, J.; Gouarin, J.; Freymuth, F. J. Virol. Methods 2003, 109, 39-45.
21. Hu, A.; Colella, M.; Tam, J. S.; Rappaport, R.; Cheng, S. J. Clin. Microbiol. 2003, 41, 149-154.
22. Nettikadan, S. R.; Johnson, J. C.; Vengasandra, S. G.; Muys, J.; Henderson, E.; Nanotechnology 2004, 15, 383-389.
23. Patolsky, F.; Zheng, G.; Hayden, O.; Lakadamyall, M.; Zhuang, X.; Lieber, C. M. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 14017-14022.
24. Perez, J. M.; Simeone, J.; Saeki, Y.; Josephson, L.; Weissieder, R. J. Am. Chem. Soc. 2003, 125, 10192-10193.